The pharmaceutical community is abuzz about retatrutide, a new dual GIP and GLP-1 target that’s showing impressive promise in {weight loss trials. Early findings from the SURPASS-2 study suggest that this treatment https://bookmarkssocial.com/story21507106/retatrutide-the-new-weight-loss-hope